x testing testing

Sectors - Health Care  

Are women wearing too much make-up to work?

A study by officebroker.com has revealed that more than a third of bosses think women are wearing too much make-up in the office

Women more stressed by commuting than men

Women experience more stress as a result of their daily commute than men, according to new research

Chewing your way to health in Austria

Whether you need to de-stress, lose weight or just take some much needed me-time away from the pressures of work, Viva Mayr health clinic could be the answer to your prayers

Hotels will enable 'virtual love making' by 2030

Business travellers in the future will be able to recreate their home bedroom in a hotel room and make love with their partner remotely, according to a new study from Travelodge

CEOs call for bipartisan legislation to reduce health care costs

A September 2009 report issued by Business Roundtable and prepared by Hewitt Associates found that if present health care cost trends continue, the cost to provide an employee with health care will increase from $10,000 to $28,000 over ten years.

Employee health essential for staff retention: survey

A recent survey of British employees by healthcare provider Simplyhealth shows that one in two UK staff say their mental and physical wellbeing was ignored by their employer during the economic downturn. Now that the market is beginning to recover, over 45 percent say they will start looking for a new job.

How user-centric design thinking can save lives

Despite new technologies, the business community remains fixated on traditional ways of displaying data, especially within the healthcare industry.

Shire plc Supports Rare Disease Day 2010

Shire plc and other pharmaceutical companies are calling attention to Rare Disease Day and actively showing their support.

AstraZeneca cancer drug fails trial, shares drop

AstraZeneca’s shares were down today following the failure of the company’s experimental cancer drug Recentin, generically known as cediranib, against Roche's Avastin. The drug did not meet its primary endpoint in the Horizon phase III study, a negative result expected by analysts.


Featured Articles + MORE Featured Articles >>